# Florence Duffaud

Source: https://onco.cc/people/florence-duffaud/  
OnCo record `florence-duffaud` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Marseille oncologist who led REGOBONE, the trial that showed regorafenib delays progression in metastatic osteosarcoma and other bone sarcomas.

## Summary

Florence Duffaud is a medical oncologist at Hôpital de la Timone in Marseille and a leader of the French Sarcoma Group. She was first author of the 2019 Lancet Oncology report of the osteosarcoma cohort of REGOBONE, the randomised phase 2 trial in which regorafenib improved progression-free survival compared with placebo in metastatic osteosarcoma after chemotherapy; other cohorts studied Ewing sarcoma, chondrosarcoma and chordoma.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: sarcoma; trialist
- Role: Medical oncologist, Hôpital de la Timone, Aix-Marseille University
- Specialisms: Bone sarcoma; Gastrointestinal stromal tumour; Kinase inhibitors in sarcoma

## Connected records

- cancers: [Chondrosarcoma](https://onco.cc/cancers/chondrosarcoma/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille](https://onco.cc/institutions/ap-hm-timone/)
- trials: [REGOBONE](https://onco.cc/trials/regobone/)

---
JSON: https://onco.cc/api/v1/entities/florence-duffaud.json